<p><strong>Pediatric Use</strong>: The safety and effectiveness of Brigatinib in pediatric patients have not been established.<br />
<br />
<strong>Geriatric Use</strong>: Of the 359 patients enrolled in the ALTA 1L Brigatinib arm and in ALTA, 26.7% were 65 and older<br />
and 7.5% were 75 and older. No overall differences in safety or effectiveness were observed between patients &ge;65 years and younger patients.<br />
<br />
<strong>Hepatic Impairment</strong>: No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A) or<br />
moderate hepatic impairment (Child-Pugh B). Reduce the dose of Brigatinib for patients with severe hepatic impairment (Child-Pugh C)<br />
<br />
<strong>Renal Impairment</strong>: No dose adjustment is recommended for patients with mild or moderate renal impairment ClCr 30 to 89 mL/min by Cockcroft-Gault. Reduce the dose of Brigatinib for patients with severe renal impairment (ClCr 15 to 29 mL/min)</p>